Nutshell Therapeutics has garnered $20 million in a Series A round of funding led by Matrix Partners China. In a separate development, Kolmostar has secured about 100 million yuan ($16 million) in a Series A+ round led by CTC Capital.
Register now to enjoy 3 free articles per month,
or log in to continue reading.
Stay informed with complimentary articles each month
Gain access to our exclusive newsletters delivered directly to your inbox
Be the first to know about all our summits!
Already a Subscriber? Log in
